ERBB2 and breast cancer: Currently, most HER2+ breast cancer patients are treated with anti-HER2 therapies, and because a substantial fraction of treated patients later suffers distant relapse relapses due to therapy resistance, we sought to determine the relationship between PPP2R2B expression and therapeutic outcome.